- Home
- SRZN vs FGEN Comparison
SRZN vs FGEN Comparison
Compare SRZN & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- FGEN
- Stock Information
- Founded
- SRZN 2015
- FGEN 1993
- Country
- SRZN United States
- FGEN United States
- Employees
- SRZN N/A
- FGEN N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- FGEN Health Care
- Exchange
- SRZN Nasdaq
- FGEN Nasdaq
- Market Cap
- SRZN 38.1M
- FGEN 34.5M
- IPO Year
- SRZN N/A
- FGEN 2014
- Fundamental
- Price
- SRZN $10.57
- FGEN $0.40
- Analyst Decision
- SRZN
- FGEN
- Analyst Count
- SRZN 0
- FGEN 0
- Target Price
- SRZN N/A
- FGEN N/A
- AVG Volume (30 Days)
- SRZN 49.1K
- FGEN 996.1K
- Earning Date
- SRZN 11-06-2024
- FGEN 11-12-2024
- Dividend Yield
- SRZN N/A
- FGEN N/A
- EPS Growth
- SRZN N/A
- FGEN N/A
- EPS
- SRZN N/A
- FGEN N/A
- Revenue
- SRZN $10,000,000.00
- FGEN $180,015,000.00
- Revenue This Year
- SRZN N/A
- FGEN $19.67
- Revenue Next Year
- SRZN N/A
- FGEN N/A
- P/E Ratio
- SRZN N/A
- FGEN N/A
- Revenue Growth
- SRZN N/A
- FGEN 16.15
- 52 Week Low
- SRZN $6.00
- FGEN $0.18
- 52 Week High
- SRZN $16.19
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- SRZN 54.47
- FGEN 58.65
- Support Level
- SRZN $9.50
- FGEN $0.34
- Resistance Level
- SRZN $11.27
- FGEN $0.37
- Average True Range (ATR)
- SRZN 1.10
- FGEN 0.04
- MACD
- SRZN 0.01
- FGEN -0.00
- Stochastic Oscillator
- SRZN 41.36
- FGEN 76.07
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.